Literature DB >> 25901151

Determination of bosentan in pharmaceutical preparations by linear sweep, square wave and differential pulse voltammetry methods.

Alptug Atila1, Bilal Yilmaz1.   

Abstract

In this study, simple, fast and reliable cyclic voltammetry (CV), linear sweep voltammetry (LSV), square wave voltammetry (SWV) and differential pulse voltammetry (DPV) methods were developed and validated for determination of bosentan in pharmaceutical preparations. The proposed methods were based on electrochemical oxidation of bosentan at platinum electrode in acetonitrile solution containing 0.1 M TBACIO4. The well-defined oxidation peak was observed at 1.21 V. The calibration curves were linear for bosentan at the concentration range of 5-40 µg/mL for LSV and 5-35 µg/mL for SWV and DPV methods, respectively. Intra- and inter-day precision values for bosentan were less than 4.92, and accuracy (relative error) was better than 6.29%. The mean recovery of bosentan was 100.7% for pharmaceutical preparations. No interference was found from two tablet excipients at the selected assay conditions. Developed methods in this study are accurate, precise and can be easily applied to Tracleer and Diamond tablets as pharmaceutical preparation.

Entities:  

Keywords:  Bosentan; Cyclic voltammetry; Differential pulse voltammetry; Linear sweep voltammetry; Square wave voltammetry

Year:  2015        PMID: 25901151      PMCID: PMC4403060     

Source DB:  PubMed          Journal:  Iran J Pharm Res        ISSN: 1726-6882            Impact factor:   1.696


  12 in total

1.  Voltammetric behavior and quantification of the sedative-hypnotic drug chlordiazepoxide in bulk form, pharmaceutical formulation and human serum at a mercury electrode.

Authors:  G B El-Hefnawey; I S El-Hallag; E M Ghoneim; M M Ghoneim
Journal:  J Pharm Biomed Anal       Date:  2004-01-27       Impact factor: 3.935

2.  Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.

Authors:  Mikayla L Spangler; Shailendra Saxena
Journal:  Clin Ther       Date:  2010-01       Impact factor: 3.393

3.  Differential pulse voltammetric determination of carvedilol in tablets dosage form using glassy carbon electrode.

Authors:  A Radi; T Elmogy
Journal:  Farmaco       Date:  2004-11-11

Review 4.  Endothelin receptor antagonists.

Authors:  Sophie Motte; Kathleen McEntee; Robert Naeije
Journal:  Pharmacol Ther       Date:  2005-10-10       Impact factor: 12.310

5.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

Authors:  V V McLaughlin; D E Genthner; M M Panella; S Rich
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

6.  Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection.

Authors:  B Lausecker; B Hess; G Fischer; M Mueller; G Hopfgartner
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-11-10

7.  Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Marius M Hoeper; Thorsten Kramm; Heinrike Wilkens; Christine Schulze; Hans Joachim Schäfers; Tobias Welte; Eckhard Mayer
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Authors:  M Clozel; V Breu; G A Gray; B Kalina; B M Löffler; K Burri; J M Cassal; G Hirth; M Müller; W Neidhart
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

9.  Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.

Authors:  M M Hoeper; N Taha; A Bekjarova; R Gatzke; E Spiekerkoetter
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

10.  Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt.

Authors:  J K Votava-Smith; G S Perens; J C Alejos
Journal:  Pediatr Cardiol       Date:  2007-06-11       Impact factor: 1.838

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.